A Community Health Center Buyback Program to Reduce the Supply of Opioids to Secondary Users
How to cite
Modestino, Alicia; Alam, Md Noor E; Young, Gary. 2019. "A Community Health Center Buyback Program to Reduce the Supply of Opioids to Secondary Users." AEA RCT Registry. AEARCTR-0004041. https://doi.org/10.1257/rct.4041-1.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Secure disposal of unused medications is one strategy to reduce the availability of opioids for diversion or abuse to secondary users after they have been dispensed. Are patients more likely to return unused opioids when informed and incentivized about a medication disposal program compared to passively observing a disposal kiosk in their pharmacy? We hypothesize that informing patients at the point of dispensing the medication, sending reminders via text message, and providing a financial incentive can significantly boost return rates. Our proposed pilot intervention will take place at five in-house community health center pharmacies in Massachusetts yielding a potential sample size of 2,400 acute opioid prescriptions over 12 months that will be randomized across treatment and control groups. We will measure the percent of patients returning opioids as well as the amount and type of medication returned across both groups. We will also compare the amount returned to the amount prescribed by type of medication to better understand whether the program has an impact on usage and refills. Finally, we will explore the degree of heterogeneity in outcomes across different groups according to patient characteristics that predict opioid addiction such as age, gender, and diagnosis.
Intervention
We seek to provide proof of concept for an opioid buy-back program that could reduce the flow of opioids from patients to secondary users and the black market. To study the effectiveness of the intervention, we will randomly assign patients to receive information about the buyback program when the prescription is filled including details on the financial incentive and reminder text messages. We will assess the direct impacts of the program based on the number of patients that take up the buyback and the total quantity of opioid medications that are returned. We will also explore how the effect varies across different groups of patients (e.g. age range, gender, English proficiency, underlying reason for prescription) as well as whether there are any program spillovers to patients that not served by the community health center.
Implementing Partner: A community health care center in Massachusetts with five in-house pharmacy locations in the same city will implement the program. Serving a culturally diverse population, the community health center is responsive to emerging community needs and has developed programs and services designed to improve access to care as well as improve the quality of life for patients.
Target Population: The intervention will target patients prescribed an opioid for an acute diagnosis such as surgery, injury, or acute pain at all five of the community health center’s in-house pharmacy sites. Acute users will be identified as having an opioid prescription for a supply of 14 days or less.
Treatment Arms: There will be two main treatment arms that will be implemented across different pharmacy locations. At the main location, patients will be randomly assigned to receiving either no information or information on how to return unused medication plus the financial incentive. At the other four locations, patients will be randomly assigned to receiving either no information or information on how to return unused medication (e.g., no financial incentive). One of the larger sites in the second treatment arm, will also receive a text notification at the end of the month to remind them about the disposal program when their prescription is likely to be completed.
Randomization: To minimize contamination, patients will be randomized into the treatment and control groups within sites but across calendar days. The randomization will occur ex-ante and each week the staff will be provided with a schedule to indicate which days are designated for patient assignment to the intervention group and instructed to apply the intervention on only those days that week. Note that patients receiving an opioid prescription at locations other than the main site will only be informed on weekdays since those locations are not open on the weekends.
IRB Approval: The research team has obtained IRB approval from Northeastern University. All data provided by the pharmacy will be de-identified with all personally identifiable information (PII) such as first and last name, date of birth, and Rx number and date removed before the data is transmitted to the research team.
Experimental design
We seek to provide proof of concept for an opioid buy-back program that could reduce the flow of opioids from patients to secondary users and the black market. To study the effectiveness of the intervention, we will randomly assign patients to receive information about the buyback program when the prescription is filled including details on the financial incentive and reminder text messages. We will assess the direct impacts of the program based on the number of patients that take up the buyback and the total quantity of opioid medications that are returned. We will also explore how the effect varies across different groups of patients (e.g. age range, gender, English proficiency, underlying reason for prescription) as well as whether there are any program spillovers to patients that not served by the community health center.
Implementing Partner: A community health care center in Massachusetts with five in-house pharmacy locations in the same city will implement the program. Serving a culturally diverse population, the community health center is responsive to emerging community needs and has developed programs and services designed to improve access to care as well as improve the quality of life for patients.
Target Population: The intervention will target patients prescribed an opioid for an acute diagnosis such as surgery, injury, or acute pain at all five of the community health center’s in-house pharmacy sites. Acute users will be identified as having an opioid prescription for a supply of 14 days or less.
Treatment Arms: There will be two main treatment arms that will be implemented across different pharmacy locations. At the main location, patients will be randomly assigned to receiving either no information or information on how to return unused medication plus the financial incentive. At the other four locations, patients will be randomly assigned to receiving either no information or information on how to return unused medication (e.g., no financial incentive). One of the larger sites in the second treatment arm, will also receive a text notification at the end of the month to remind them about the disposal program when their prescription is likely to be completed.
Randomization: To minimize contamination, patients will be randomized into the treatment and control groups within sites but across calendar days. The randomization will occur ex-ante and each week the staff will be provided with a schedule to indicate which days are designated for patient assignment to the intervention group and instructed to apply the intervention on only those days that week. Note that patients receiving an opioid prescription at locations other than the main site will only be informed on weekdays since those locations are not open on the weekends.
IRB Approval: The research team has obtained IRB approval from Northeastern University. All data provided by the pharmacy will be de-identified with all personally identifiable information (PII) such as first and last name, date of birth, and Rx number and date removed before the data is transmitted to the research team.
Design details
Cited by
No citation data available for this registration yet.